Fulvestrant can therefore be considered as alternative therapy to anastrozole or exemestane in postmenopausal women with locally advanced or metastatic breast cancer that has recurred on prior adjuvant endocrine therapy or progressed on prior endocrine therapy for advanced disease .
A systematic review was undertaken to examine all available evidence to develop and support clinical recommendations regarding the use of fulvestrant ( Faslodex ® ) as systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women .
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
This report presents the results of a survival up date based on the combined data from two studies that compared the efficacy and tolerability of anastrozole ( 1 or 10 mg once daily ) , a selective , nonsteroidal aromatase inhibitor administered orally , and megestrol acetate ( 40 mg 4 times daily ) in the treatment of postmenopausal women with advanced breast carcinoma whose disease had progressed after treatment with tamoxifen
Fulvestrant can therefore be considered as alternative therapy to anastrozole or exemestane in postmenopausal women with locally advanced or metastatic breast cancer that has recurred on prior adjuvant endocrine therapy or progressed on prior endocrine therapy for advanced disease .
A systematic review was undertaken to examine all available evidence to develop and support clinical recommendations regarding the use of fulvestrant ( Faslodex ® ) as systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women .